



Genetic Research on Hearing Loss

Guest Editor:

Dr. Anna Morgan

Institute for Maternal and Child
Health—IRCCS, Burlo Garofolo,
34127 Trieste, Italy

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Hearing loss (HL) is the most common sensory impairment worldwide. It is characterized by a high clinical/genetic heterogeneity with ~123 genes reported so far and more than 400 HL syndromes described. Genetic factors account for 50–60% of all the cases; however, despite the efforts made in recent years, many patients still lack a final molecular diagnosis.

This Special Issue aims to collect reviews and original articles on recent investigations of the molecular basis of hearing loss, both syndromic and non-syndromic, as well as age-related hearing loss. All manuscripts, both experimental and theoretical contributions, should highlight:

1. The molecular mechanisms at the level of single genes/proteins or their networks;
2. The benefit from the vast amounts of information that can be garnered from genetic work in this field;
3. New possible candidate genes for monogenic and complex forms of HL





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)